BACKGROUND AND OBJECTIVES: Little is known about the performance of plasma cystatin C (CysC) in patients undergoing cardiopulmonary bypass (CPB) and its utility in the early diagnosis of acute kidney injury (AKI). In this post hoc analysis, the goal was to determine whether plasma cystatin C, measured 2 hours after the conclusion of CPB, is a reliable marker of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma CysC was measured in 150 patients undergoing CPB at the following times: preoperatively, 2 hours after the conclusion of CPB, postoperative day 1, and postoperative day 2. Plasma CysC levels were related to the development of AKI as defined by an increase in serum creatinine of >or=50% or >or=0.3 mg/dl from baseline up to 3 days postoperative. Mixed linear models were used to evaluate the relationship of serial plasma CysC values with AKI. The discriminatory capacity of plasma CysC was estimated using receiver operating characteristic curves. Logistic regression was utilized to assess the adjusted relationship between plasma CysC and subsequent AKI. RESULTS: AKI developed in 47 (31.3%) patients. Plasma CysC was higher at all times among patients who developed AKI compared with those who did not (P < 0.0001). The discriminatory capacity of plasma CysC measured preoperatively and 2 hours after the conclusion of CPB was modest. CONCLUSIONS: Serial measures of plasma CysC are highly correlated with the development of AKI. However, the discriminatory capacity of plasma CysC as an early marker of AKI remains limited.
BACKGROUND AND OBJECTIVES: Little is known about the performance of plasma cystatin C (CysC) in patients undergoing cardiopulmonary bypass (CPB) and its utility in the early diagnosis of acute kidney injury (AKI). In this post hoc analysis, the goal was to determine whether plasma cystatin C, measured 2 hours after the conclusion of CPB, is a reliable marker of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma CysC was measured in 150 patients undergoing CPB at the following times: preoperatively, 2 hours after the conclusion of CPB, postoperative day 1, and postoperative day 2. Plasma CysC levels were related to the development of AKI as defined by an increase in serum creatinine of >or=50% or >or=0.3 mg/dl from baseline up to 3 days postoperative. Mixed linear models were used to evaluate the relationship of serial plasma CysC values with AKI. The discriminatory capacity of plasma CysC was estimated using receiver operating characteristic curves. Logistic regression was utilized to assess the adjusted relationship between plasma CysC and subsequent AKI. RESULTS: AKI developed in 47 (31.3%) patients. Plasma CysC was higher at all times among patients who developed AKI compared with those who did not (P < 0.0001). The discriminatory capacity of plasma CysC measured preoperatively and 2 hours after the conclusion of CPB was modest. CONCLUSIONS: Serial measures of plasma CysC are highly correlated with the development of AKI. However, the discriminatory capacity of plasma CysC as an early marker of AKI remains limited.
Authors: Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: Stefan Herget-Rosenthal; Günter Marggraf; Johannes Hüsing; Frauke Göring; Frank Pietruck; Onno Janssen; Thomas Philipp; Andreas Kribben Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Madhav Swaminathan; Barbara G Phillips-Bute; Peter J Conlon; Peter K Smith; Mark F Newman; Mark Stafford-Smith Journal: Ann Thorac Surg Date: 2003-09 Impact factor: 4.330
Authors: Andrea Lassnigg; Daniel Schmidlin; Mohamed Mouhieddine; Lucas M Bachmann; Wilfred Druml; Peter Bauer; Michael Hiesmayr Journal: J Am Soc Nephrol Date: 2004-06 Impact factor: 10.121
Authors: Michael Haase; Rinaldo Bellomo; Prasad Devarajan; Qing Ma; Michael R Bennett; Martin Möckel; George Matalanis; Duska Dragun; Anja Haase-Fielitz Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: Aferdita Spahillari; Chirag R Parikh; Kyaw Sint; Jay L Koyner; Uptal D Patel; Charles L Edelstein; Cary S Passik; Heather Thiessen-Philbrook; Madhav Swaminathan; Michael G Shlipak Journal: Am J Kidney Dis Date: 2012-07-17 Impact factor: 8.860
Authors: John Richard Prowle; Paolo Calzavacca; Elisa Licari; E Valentina Ligabo; Jorge E Echeverri; Sean M Bagshaw; Anja Haase-Fielitz; Michael Haase; Vaughn Ostland; Eisei Noiri; Mark Westerman; Prasad Devarajan; Rinaldo Bellomo Journal: Ren Fail Date: 2015-01-14 Impact factor: 2.606
Authors: Asada Leelahavanichkul; Ana Carolina P Souza; Jonathan M Street; Victor Hsu; Takayuki Tsuji; Kent Doi; Lingli Li; Xuzhen Hu; Hua Zhou; Parag Kumar; Jürgen Schnermann; Robert A Star; Peter S T Yuen Journal: Am J Physiol Renal Physiol Date: 2014-08-20
Authors: Lorraine Lau; Zubaida Al-Ismaili; Maya Harel-Sterling; Michael Pizzi; Jillian S Caldwell; Melissa Piccioni; Larry C Lands; Theresa Mottes; Prasad Devarajan; Stuart L Goldstein; Michael R Bennett; Michael Zappitelli Journal: Pediatr Nephrol Date: 2016-10-14 Impact factor: 3.714
Authors: Pranav S Garimella; Bertrand L Jaber; Hocine Tighiouart; Orfeas Liangos; Michael R Bennett; Prasad Devarajan; Tarek M El-Achkar; Mark J Sarnak Journal: Clin J Am Soc Nephrol Date: 2016-10-26 Impact factor: 8.237
Authors: Michael G Shlipak; Steven G Coca; Zhu Wang; Prasad Devarajan; Jay L Koyner; Uptal D Patel; Heather Thiessen-Philbrook; Amit X Garg; Chirag R Parikh Journal: Am J Kidney Dis Date: 2011-05-20 Impact factor: 8.860
Authors: Rajit K Basu; Hector R Wong; Catherine D Krawczeski; Derek S Wheeler; Peter B Manning; Lakhmir S Chawla; Prasad Devarajan; Stuart L Goldstein Journal: J Am Coll Cardiol Date: 2014-12-30 Impact factor: 24.094